Multiple Myeloma News
Here are all the latest news articles written by The Beacon’s staff.
For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, Kyprolis, Pomalyst, Revlimid, thalidomide, Velcade, and Zometa.
For news articles about potential new myeloma treatments, click on these links:
BT-062, daratumumab, elotuzumab, ixazomib (MLN9708), marizomib (NPI-0052), panobinostat, perifosine, Treanda (bendamustine), and Zolinza (vorinostat).
For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathy, secondary cancer, smoldering multiple myeloma, and stem cell transplants.
Read the full story »
A subanalysis of recent clinical trial results shows good response rates for single-agent Kyprolis in heavily pretreated multiple myeloma patients with high-risk chromosomal abnormalities.
Specifically, the investigators found that the response rates for patients with high-risk chromosomal abnormalities were similar to those for patients without high-risk chromosomal abnormalities.
However, the researchers also found that response duration and overall survival remained significantly lower in patients with high-risk chromosomal abnormalities.
Nevertheless, the researchers describe the results as encouraging, and they suggest that treatment with Kyprolis (carfilzomib) may be beneficial for patients…
Read the full story »
The American Society of Clinical Oncology will hold its 49th annual meeting May 31 through June 4 in Chicago.
Similar to previous years, more than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Building Bridges to Conquer Cancer.”
During the meeting, there will be presentations and seminars about all areas of cancer, including many focused specifically on multiple myeloma. The ASCO website currently lists more than
Read the full story »
Results from a recent European Phase 3 clinical trial indicate that a few months of treatment with Velcade may improve the outcomes of multiple myeloma patients who recently underwent a stem cell transplant.
Specifically, patients who received Velcade (bortezomib) following transplantation, which is known as “consolidation therapy,” had a longer median progression-free survival than those who did not receive additional therapy after transplantation. Their response to transplantation was also more likely to improve with Velcade consolidation therapy.
However, the researchers found that Velcade consolidation therapy appeared to be…
BMI, Not Physical Activity, Associated With Risk Of Myeloma – Results of a large U.S.-based study sponsored by the AARP found that across all age groups, people with higher body mass index (BMI) were more likely to develop multiple myeloma. However, physical activity level at any age did not impact the likelihood of developing myeloma. Previous studies have investigated whether obesity increases a person’s risk of developing myeloma, but the results have been inconsistent. For more information, see the study in American Journal of Epidemiology (abstract).
Study On Timing Of Stem Cell Transplantation Shows Early Transplant Improves Progression-Free Survival – Results from a small, retrospective study conducted in China show that newly diagnosed myeloma patients who received Velcade (bortezomib)-based initial therapy and a stem cell transplant had significantly longer progression-free survival (42 months) compared to previously-treated patients who received the same combination of treatments at relapse (27 months). Although there was not a statistically significant difference in overall survival between the two groups of patients, there was a trend favoring early transplantation: five years from diagnosis, about 80 percent of the early-transplant patients were still alive, versus about 50 percent of the delayed-transplant patients. The trend to better survival in the early-transplant group, however, may be due to the fact that all patients in this group received a novel therapy (Velcade) as part of their initial therapy immediately after diagnosis. This was not the case for the late-transplant patients, some of whom received older treatment regimens as their initial treatment immediately after diagnosis. In both groups of patients, stem cell transplantation deepened the response to treatment. The transplant process increased the combined rate of near-complete and complete responses from 70 percent to 85 percent in the early-transplant patients, and from 56 percent to 81 percent in the late-transplant patients. For more information, see the study in the Chinese Journal of Cancer Research.
Study Sheds Light On Efficacy And Safety Of Preparative Therapy For Donor Stem Cell Transplantation – An Italian study of 196 myeloma patients who underwent donor (allogeneic) stem cell transplantation compared the outcomes of those who received myeloablative preparative therapy (high-intensity treatment that causes irreversibly low blood cell counts and requires stem cell transplantation) versus reduced-intensity preparative therapy (causes low blood cell counts and should be accompanied by stem cell transplantation) versus non-myeloablative preparative therapy (causes minimal reductions in blood cell counts and does not need to be accompanied by stem cell transplantation). All transplants were done using stem cells donated by unrelated donors. Patients had received a median of three lines of therapy prior to their donor transplant, and 89 percent of the patients had previously undergone at least one autologous (own) stem cell transplant. The results of the study show that patients who received non-myeloablative or myeloablative therapy had longer event-free and overall survival than those who received reduced-intensity therapy. Event-free survival was 10 months for those who received myeloablative therapy, 6 months for reduced-intensity therapy, and 13 months for non-myeloablative therapy. Overall survival was 29 months, 11 months, and 32 months, respectively. However, patients who received myeloablative therapy were most likely to experience fatal transplant-related complications. The one-year treatment related mortality rates were 29 percent for myeloablative therapy, 20 percent for reduced-intensity therapy, and 25 percent for non-myeloablative therapy. At three years, the rates were 37 percent, 31 percent, and 30 percent, respectively. The study investigators conclude that long-term disease control is still challenging and that more studies are needed to define the role of donor transplantation for myeloma using stem cells from unrelated donors. For more information, see the study in Biology of Blood and Marrow Transplantation (abstract).